


INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) May 9, 2006 PTO Form 1449				Attorney Docket No. 056291-5181		Application No. 10/507,164	
				Applicants Sue Ann CARTLIDGE		PAGE 1 of 1	
				Filing Date September 9, 2004		Group Art Unit 1615 1644	
U.S. PATENT DOCUMENTS							
Initial		Document No.		Name	Class	Sub-Class	Filing Date
FOREIGN PATENT DOCUMENTS							
		Document No.	Date	Country	Class	Sub-Class	Translation
PH	1.	WO 0229090	April 11, 2002	WIPO			Yes
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
PH	2.	Clauss M (2000) Molecular biology of the VEGF and the VEGF receptor family Semin Thromb Hemost. 26(5)561-569					
	3.	Cullinan-Bove K et al. (1993) Vascular endothelial growth factor/vascular permeability factor expression in the rat uterus rapid stimulation by estrogen correlates with estrogen-induced increases in uterine capillary permeability and growth Endocrinology 133 829-837					
	4.	Cunningham SA et al. (1997) Interactions of FLT-1 and KDR with phospholipase C gamma. Identification of the phosphotyrosine binding sites Biochem. Biophys. Res. Comm. Biochem. Biophys. Res. Comm. 240635-639					
	5.	Dougher M et al. (1999) Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization Oncogene 18(8)1619-1627					
	6.	Fan TP et al. (1995) Controlling the vasculature angiogenesis, anti-angiogenesis and vascular targeting of gene therapy Trends Pharmacol Sci. 16(2)57-66					
	7.	Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease Nature Medicine. 1(1)27-31					
	8.	Karkkainen MJ et al. (2000) Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis Oncogene 195598-5605					
	9.	Kendall RL et al. (1999) Vascular Endothelial Growth Factor Receptor KDR Tyrosine Kinase Activity Is Increased by Autophosphorylation of Two Activation Loop Tyrosine Residues J Biol Chem 274(10)6453-6460					
	10.	McMahon G (2002) VEGF receptor signaling in tumor angiogenesis Oncologist. 5 Suppl 13-10					
	11.	Ratcliffe KE et al. (2002) Sck is expressed in endothelial cells and participates in vascular endothelial growth factor-induced signaling Oncogene 21(41)6307-6316					
	12.	Senger DR et al. (1993) Vascular Permeability Factor (VPF, VEGF) in Tumor Biology Cancer Met Reviews 12303-324					
	13.	Terman BI et al. (1991) Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 61677-1683					
	14.	Terman BI et al. (1992) Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor Biochem Biophys Res Commun. 187(3)1579-1586					
	15.	Warner AJ et al. (2000) The Shc-related adaptor protein, Sck, forms a complex with the vascular-endothelial-growth-factor receptor KDR in transfected cells Biochem J. 347(Pt 2)501-509					
↓	16.	Zeng H (2001) Tyrosine Residues 951 and 1059 of Vascular Endothelial Growth Factor Receptor-2 (KDR) Are Essential for Vascular Permeability Factor/Vascular Endothelial Growth Factor-induced Endothelium Migration and Proliferation, Respectively J. Biol. Chem. 276(35)32714-32719					
Examiner		/Phuong Huynh/		Date Considered		11/14/2006	
Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) PTO Form 1449				Attorney Docket No. 056291-5181		Application No. 10/507,164			
				Applicants: Sue Ann CARTLIDGE				PAGE 1 of 1	
				Filing Date: September 9, 2004				1644 Group Art Unit: 1615	

U.S. PATENT DOCUMENTS							
Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date	

FOREIGN PATENT DOCUMENTS							
Document No.	Date	Country	Class	Sub-Class	Translation		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
PH ↓	1. 2. 3. 4. 5. 6. 7. 8.	Wood et al. (2000) "PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration" <i>Cancer Res.</i> 60(8): 2178-2189 Igarashi et al. (1998) "Tyrosine 1213 of Flt-1 Is a Major Binding Site of Nck and SHP-2" <i>Biochemical and Biophysical Research Communications</i> 246(1): 95-99 (p. 98, right-hand column, last paragraph-p. 99; figs. 2-4) Carroll et al. (1999) "KDR activation in astrocytic neoplasms" <i>Cancer</i> 86(7): 1335-1341 (Abstract) Takahashi et al. (2001) "A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-g and DNA synthesis in vascular endothelial cells" <i>EMBO J.</i> 20(11): 2768-2778 (Cited in application, abstract, fig. 1, pp. 2769, left-hand column, para. 1) Menrad et al. (1997) "Novel antibodies directed against the extracellular domain of the human VEGF-receptor type II" <i>Hybridoma</i> 16(5): 465-471 (Abstract, p. 469) Zhu et al. (1999) "Inhibition of vascular endothelial growth factor induced mitogenesis of human endothelial cells by a chimeric anti- kinase insert domain-containing receptor antibody" <i>Cancer Letters</i> 136(2): 203 - 213 (Abstract, p. 210, left-hand column, last paragraph - right-hand column) Rockwell et al. (1995) "In-vitro neutralization of vascular endothelial growth factor activation of flk-1 by a monoclonal antibody" <i>Mol. Cell. Diff.</i> 3(1): 91-109 (p. 102, paragraphs 2,3, abstract) Meyer et al. (2002) "The Presence of a Single Tyrosine Residue at the Carboxyl Domain of Vascular Endothelial Growth Factor Receptor-2/FLK-1 Regulates Its Autophosphorylation and Activation of Signaling Molecules" <i>J. Biol. Chem.</i> , 277(30): 27081-27087 (Abstract, figs. 1, 4-6)

Examiner /Phuong Huynh/	Date Considered 11/14/2006
-------------------------	----------------------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (modified) To: U.S. Department of Commerce Patent and Trademark Office IDS: 09/09/2004				Attorney Docket No. 056291-5181		Client Ref. 10/507164 100676-1P US	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Applicant: Sue Ann CARTLIDGE			
				Appln. No.: To Be Assigned			
				Filing Date: Concurrently			
				Examiner: Unassigned		Group Art Unit: 1644 Unassigned	
Date: September 9, 2004 Page 1 of 1							
U.S. PATENT DOCUMENTS							
Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)	
AR							
BR							
CR							
FOREIGN PATENT DOCUMENTS							
	Document Number	Date MM/YYYY	Country	Inventor/Applicant Name	English Abstract		Translation Readily Available
					Enclosed	No	Enclosed
DR							
ER							
FR							
GR							
HR							
OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)							
PH	IR	Wood et al., CANCER RESEARCH, vol. 60, no. 8, 15 Apr. 2000, pp. 2178-2189, XP000971163, ISSN: 0008-5472, abstract					
	JR	Igarashi Katsuhide et al., BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 246, no. 1, 8 May 1998, pp. 95-99, XP002251094, ISSN: 0006-291X, p. 98, right-hand column, last paragraph-p. 99; figs. 2-4					
	KR	Carrol Rona et al., CANCER, vol. 86, no. 7, 1 October 1999, pp. 1335-1341, XP002251095, ISSN: 0008-543X, abstract					
	LR	Takahashi et al., THE EMBO JOURNAL, England, vol. 20, no. 11, 1 June 2001, pp. 2768-2778, XP002251096, ISSN: 0261-4189, cited in application, abstract, fig. 1, pp. 2769, left-hand column, para. 1					
	MR	Menrad et al., HYBRIDOMA, vol. 16, no. 5, 1 October 1997, pp. 465-471, XP002052460, ISSN: 0272-457X, abstract, p. 469					
	NR	Zhu et al., CANCER LETTERS, vol. 136, no. 2, 1 March 1999, p[p. 203-213, XP002251097, ISSN: 0304-3835, abstract, p. 210, left-hand column, last paragraph - right-hand column					
	OR	Rockwell et al., MOLLECULAR AND CELLULAR DIFFERENTIATION, vol. 3, no. 1, 1995, pp. 91-109, XP002052455, ISSN: 1065-3074, p. 102, paragraphs 2,3, abstract					
↓	PR	Meyer et al., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 30, 22 May 2002, pp. 27081-27087, XP002251098, July 28, 2002, ISSN: 0021-9258, abstract, figs. 1, 4-6					
Examiner /Phuong Huynh/				Date Considered: 11/14/2006			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							